

MDM2 inhibition: an important step forward in cancer t

Leukemia

34, 2858-2874

DOI: [10.1038/s41375-020-0949-z](https://doi.org/10.1038/s41375-020-0949-z)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New Perspectives on Polycythemia Vera: From Diagnosis to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5805.	4.1	27
3	MDM2 inhibitors: Targeting p53-MDM2 interaction to anti-cancer. <i>E3S Web of Conferences</i> , 2021, 308, 02015.	0.5	0
4	Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity. <i>Frontiers in Genetics</i> , 2021, 12, 632719.	2.3	10
5	Differential Interactome Proposes Subtype-Specific Biomarkers and Potential Therapeutics in Renal Cell Carcinomas. <i>Journal of Personalized Medicine</i> , 2021, 11, 158.	2.5	8
6	High Expression of MDM2 and the p53 Protein is Predictive Biomarkers for Poor Prognosis of Oesophageal Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 2733-2744.	1.9	2
7	Regulation of p53 stability as a therapeutic strategy for cancer. <i>Biochemical Pharmacology</i> , 2021, 185, 114407.	4.4	27
8	First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. <i>Breast Cancer Research</i> , 2021, 23, 29.	5.0	31
9	Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4071-4088.	6.4	30
10	Emerging agents and regimens for AML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 49.	17.0	104
11	MDM2 Amplified Sarcomas: A Literature Review. <i>Diagnostics</i> , 2021, 11, 496.	2.6	40
12	Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3421-3434.	4.2	11
13	Anti-PD-1 Immunotherapy and Bee Venom for Relapsed and Refractory Liposarcoma: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 668992.	2.8	3
14	Ferroptosis and its emerging roles in cardiovascular diseases. <i>Pharmacological Research</i> , 2021, 166, 105466.	7.1	126
15	Characterization of the Components and Pharmacological Effects of Mountain-Cultivated Ginseng and Garden Ginseng Based on the Integrative Pharmacology Strategy. <i>Frontiers in Pharmacology</i> , 2021, 12, 659954.	3.5	9
16	TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin. <i>Molecular Pharmacology</i> , 2021, 100, 144-154.	2.3	6
17	Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. <i>Cancers</i> , 2021, 13, 2195.	3.7	0
18	The Ubiquitin Proteasome System in Genome Stability and Cancer. <i>Cancers</i> , 2021, 13, 2235.	3.7	15
19	All activated signaling pathways lead to anaplastic large cell lymphoma (ALCL). <i>Leukemia and Lymphoma</i> , 2021, 62, 1541-1543.	1.3	0

#	ARTICLE	IF	CITATIONS
20	Dying to Surviveâ€”The p53 Paradox. <i>Cancers</i> , 2021, 13, 3257.	3.7	18
21	Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. <i>Investigational New Drugs</i> , 2021, 39, 1587-1597.	2.6	15
22	DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia. <i>Scientific Reports</i> , 2021, 11, 12148.	3.3	17
23	Imidazoles as Potential Anticancer Agents: An Update on Recent Studies. <i>Molecules</i> , 2021, 26, 4213.	3.8	69
24	MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 703442.	2.8	17
25	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. <i>Clinical Cancer Research</i> , 2021, 27, 5236-5247.	7.0	74
26	Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 98, 102223.	7.7	34
27	TP53 in Biology and Treatment of Osteosarcoma. <i>Cancers</i> , 2021, 13, 4284.	3.7	26
29	circNUDT21 promotes bladder cancer progression by modulating the miR-16-1-3p/MDM2/p53 axis. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 625-636.	5.1	10
30	Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S3-S6.	0.4	3
31	Circular RNA hsa_circ_0000073 Enhances Osteosarcoma Cells Malignant Behavior by Sponging miR-1252-5p and Modulating CCNE2 and MDM2. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 714601.	3.7	5
32	Inhibition of nonsense-mediated decay rescues p53 ^{Δ2/Δ3} isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. <i>Journal of Biological Chemistry</i> , 2021, 297, 101163.	3.4	18
33	Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemiaâ€”From Molecular Mechanisms to Clinical Relevance. <i>Cancers</i> , 2021, 13, 4820.	3.7	65
34	Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy. <i>Clinical Lung Cancer</i> , 2022, 23, 14-20.	2.6	4
35	Targeting mutant p53 for cancer therapy: direct and indirect strategies. <i>Journal of Hematology and Oncology</i> , 2021, 14, 157.	17.0	190
36	Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy. <i>Bioorganic Chemistry</i> , 2021, 116, 105273.	4.1	23
37	Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?. <i>Cells</i> , 2021, 10, 98.	4.1	23
38	Phase 1 Concentrationâ€”QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRTâ€”232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 918-926.	1.6	11

#	ARTICLE	IF	CITATIONS
39	Targeting ubiquitin signaling for cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 16.	17.1	34
40	A survey of applications of tetrahydropyrrolo-3,4-azoles and tetrahydropyrrolo-2,3-azoles in medicinal chemistry. <i>Advances in Heterocyclic Chemistry</i> , 2021, , 31-100.	1.7	6
41	Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet. <i>European Journal of Immunology</i> , 2022, 52, 34-43.	2.9	2
42	TP53 in Myelodysplastic Syndromes. <i>Cancers</i> , 2021, 13, 5392.	3.7	8
43	USP22-mediated deubiquitination of PTEN inhibits pancreatic cancer progression by inducing p21 expression. <i>Molecular Oncology</i> , 2022, 16, 1200-1217.	4.6	14
44	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. <i>Cancers</i> , 2021, 13, 5722.	3.7	17
45	Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges. <i>Cells</i> , 2021, 10, 3309.	4.1	23
46	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. <i>Advances in Biological Regulation</i> , 2021, , 100840.	2.3	4
47	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 870-881.	7.0	32
48	Identification of ZER6 Isoform p52-ZER6 as an Antitumour Therapeutic Response Determinant for MDM2-p53 Binding Inhibitors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
49	It's Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818744.	3.7	15
50	Oncogene or Tumor Suppressor: The Coordinative Role of Lysine Methyltransferase SET7/9 in Cancer Development and the Related Mechanisms. <i>Journal of Cancer</i> , 2022, 13, 623-640.	2.5	9
52	4,7-Di-O-methylnaringenin (DMNG), a naringenin derivative, activates p53 signal pathway through down-regulating MDM2. <i>Journal of Functional Foods</i> , 2022, 89, 104962.	3.4	4
53	Hinokiflavone, as a MDM2 inhibitor, activates p53 signaling pathway to induce apoptosis in human colon cancer HCT116 cells. <i>Biochemical and Biophysical Research Communications</i> , 2022, 594, 93-100.	2.1	6
54	Downregulation of CPT2 promotes proliferation and inhibits apoptosis through p53 pathway in colorectal cancer. <i>Cellular Signalling</i> , 2022, 92, 110267.	3.6	18
55	Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 147-164.	2.1	5
56	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. <i>International Review of Cell and Molecular Biology</i> , 2022, 366, 83-124.	3.2	12
57	Current strategies and progress for targeting the "undruggable" transcription factors. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2474-2481.	6.1	11

#	ARTICLE	IF	CITATIONS
58	Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation. <i>Frontiers in Chemistry</i> , 2021, 9, 735236.	3.6	22
59	E3 ligase ligand chemistries: from building blocks to protein degraders. <i>Chemical Society Reviews</i> , 2022, 51, 3487-3534.	38.1	52
60	Energetics of a protein disorderâ€“order transition in small molecule recognition. <i>Chemical Science</i> , 2022, 13, 5220-5229.	7.4	7
61	The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. <i>Blood Advances</i> , 2022, 6, 1162-1174.	5.2	10
62	Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	4
63	Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>Current Oncology Reports</i> , 2022, 24, 621-631.	4.0	6
64	Targetable Pathways in the Treatment of Retroperitoneal Liposarcoma. <i>Cancers</i> , 2022, 14, 1362.	3.7	11
65	Cross-Talk between p53 and Wnt Signaling in Cancer. <i>Biomolecules</i> , 2022, 12, 453.	4.0	15
66	Partial p53 reactivation is sufficient to induce cancer regression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 80.	8.6	11
67	Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 1592.	3.7	8
68	Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective. <i>Medicinal Research Reviews</i> , 2022, 42, 1607-1660.	10.5	20
69	Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations. <i>Experimental Hematology</i> , 2022, , .	0.4	2
70	The p53 network: cellular and systemic DNA damage responses in cancer and aging. <i>Trends in Genetics</i> , 2022, 38, 598-612.	6.7	67
71	Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas. <i>Cancers</i> , 2022, 14, 1276.	3.7	1
72	Recent advances in the treatment of polycythemia vera. <i>Leukemia and Lymphoma</i> , 2022, , 1-9.	1.3	2
73	Small-molecule MDM2 inhibitors in clinical trials for cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2022, 236, 114334.	5.5	32
74	The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2669-2678.	7.0	6
75	SOHO State of the Art Updates and Next Questions Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 652-658.	0.4	9

#	ARTICLE	IF	CITATIONS
76	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. <i>Leukemia Research</i> , 2022, 115, 106821.	0.8	3
77	Ubiquitination and deubiquitination in the regulation of epithelial-mesenchymal transition in cancer: Shifting gears at the molecular level. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022, 1869, 119261.	4.1	9
78	Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System. <i>Cells</i> , 2021, 10, 3465.	4.1	27
79	Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways. <i>Experimental Hematology and Oncology</i> , 2022, 11, 23.	5.0	4
80	Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6207-6230.	6.4	7
81	Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 871259.	3.5	2
82	Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain. <i>Biomolecules</i> , 2022, 12, 643.	4.0	4
83	The Role of E3 Ligase Pirh2 in Disease. <i>Cells</i> , 2022, 11, 1515.	4.1	5
84	CircMCTP2 (has-circ-0000658) facilitates the proliferation and metastasis of bladder carcinoma through modulating the miR-498/murine double minute-2 axis. <i>Bioengineered</i> , 2022, 13, 10734-10748.	3.2	1
85	Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5053.	4.1	22
86	MDM2-mediated ubiquitination of LKB1 contributes to the development of diabetic cataract. <i>Experimental Cell Research</i> , 2022, 417, 113191.	2.6	4
87	Kelch-like protein 3 in human disease and therapy. <i>Molecular Biology Reports</i> , 2022, 49, 9813-9824.	2.3	2
88	Recent applications of covalent chemistries in protein-protein interaction inhibitors. <i>RSC Medicinal Chemistry</i> , 2022, 13, 921-928.	3.9	7
89	PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. , 2022, 1, .		13
91	Exploiting Extracellular Vesicles Strategies to Modulate Cell Death and Inflammation in COVID-19. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
92	Medulloblastoma and the DNA Damage Response. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
93	Molecular docking of DS-3032B, a mouse double minute 2 enzyme antagonist with potential for oncology treatment development. <i>World Journal of Clinical Oncology</i> , 2022, 13, 496-504.	2.3	2
94	Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	15

#	ARTICLE	IF	CITATIONS
95	Dispirooxindole-Î²-Lactams: Synthesis via Staudinger Ketene-Imine Cycloaddition and Biological Evaluation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6666.	4.1	2
96	Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells. <i>Cancer Genetics</i> , 2022, 266-267, 57-68.	0.4	3
97	Glucocalyxin A Inhibits the Malignancies of Gastric Cancer Cells by Downregulating MDM2 and RNF6 via MiR-3658 and the SMG1-UPF mRNA Decay Pathway. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
98	KDM4 inhibitor SD49-7 attenuates leukemia stem cell <i>via</i> KDM4A/MDM2/p21^{CIP1} axis. <i>Theranostics</i> , 2022, 12, 4922-4934.	10.0	7
99	Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. <i>Cancer Treatment Reviews</i> , 2022, 109, 102433.	7.7	15
100	Long Non-coding RNAs Sponging MicroRNAs With Efficacy in Preclinical <i>In Vivo</i> Models of Esophageal Squamous Cell Cancer. <i>Anticancer Research</i> , 2022, 42, 3233-3249.	1.1	1
101	Synthesis of MDM2-p53 Inhibitor BI-0282 via a Dipolar Cycloaddition and Late-Stage Davisâ€™Beirut Reaction. <i>Organic Process Research and Development</i> , 2022, 26, 2526-2531.	2.7	2
102	LIN28B inhibition sensitizes cells to p53-restoring PPI therapy through unleashed translational suppression. <i>Oncogenesis</i> , 2022, 11, .	4.9	2
103	ZLM-7 Blocks Breast Cancer Progression by Inhibiting MDM2 via Upregulation of 14-3-3 Sigma. <i>Pharmaceuticals</i> , 2022, 15, 874.	3.8	2
104	Functional roles of E3 ubiquitin ligases in prostate cancer. <i>Journal of Molecular Medicine</i> , 2022, 100, 1125-1144.	3.9	6
105	Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma. <i>JCI Insight</i> , 2022, 7, .	5.0	5
106	Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 10183-10194.	6.4	20
107	Structural studies of antitumor compounds that target the <sc>RING</sc> domain of <sc>MDM2</sc>. <i>Protein Science</i> , 2022, 31, .	7.6	0
109	Small molecule MMri62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
110	Comprehensive Analysis of Genomic Alterations in Hepatoid Adenocarcinoma of the Stomach and Identification of Clinically Actionable Alterations. <i>Cancers</i> , 2022, 14, 3849.	3.7	3
111	p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors. <i>Acta Pharmacologica Sinica</i> , 0, , .	6.1	1
112	Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia. <i>Bioactive Materials</i> , 2023, 21, 499-510.	15.6	6
113	A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage Iâ€™III hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2

#	ARTICLE	IF	CITATIONS
114	Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies. <i>Advances in Biological Regulation</i> , 2022, , 100917.	2.3	0
115	MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment. <i>Cancers</i> , 2022, 14, 4421.	3.7	12
116	Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
117	Identification of a small-molecule RPL11 mimetic that inhibits tumor growth by targeting MDM2-p53 pathway. <i>Molecular Medicine</i> , 2022, 28, .	4.4	4
118	Asymmetric Synthesis of Tricyclic Fused Dispirooxindoles via Organocatalyzed Three-Component Cascade Reactions of 2-Pyrones and Trifluoroethylisatin Ketimines. <i>Advanced Synthesis and Catalysis</i> , 0, , .	4.3	1
119	Akt: a key transducer in cancer. <i>Journal of Biomedical Science</i> , 2022, 29, .	7.0	21
120	A comprehensive review of BET-targeting PROTACs for cancer therapy. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 73, 117033.	3.0	9
121	Fighting New Wars with old Weapons: Repurposing of Anti-Malarial Drug for Anticancer Therapy. <i>Archives of Breast Cancer</i> , 0, , 439-449.	0.5	0
122	MDM2 inhibitors-mediated disruption of mitochondrial metabolism: A novel therapeutic strategy for retinoblastoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
123	Dual Targeting of MDM4 and FTH1 by MMRi71 for Induced Protein Degradation and p53-Independent Apoptosis in Leukemia Cells. <i>Molecules</i> , 2022, 27, 7665.	3.8	1
124	Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer. <i>Current Medicinal Chemistry</i> , 2023, 30, 3668-3701.	2.4	3
125	PAHSAs reduce cellular senescence and protect pancreatic beta cells from metabolic stress through regulation of Mdm2/p53. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	10
126	The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
127	Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15104.	4.1	4
128	BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. <i>Neuro-Oncology</i> , 2023, 25, 913-926.	1.2	9
129	Prioritization of bioactive compounds envisaging yohimbine as a multi targeted anticancer agent: insight from molecular docking and molecular dynamics simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-15.	3.5	0
131	Synthesis, Docking Study, and Biological Evaluation of 2-Phenylchroman-4-one Derivatives as Murine Double Minute 2 (MDM2) Inhibitors. <i>ChemistrySelect</i> , 2023, 8, .	1.5	0
132	AMG232 inhibits the angiogenesis in glioma through p53/RBM4/VEGFR2 pathway. <i>Journal of Cell Science</i> , 0, , .	2.0	0

#	ARTICLE	IF	CITATIONS
133	Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	8.6	16
134	SLiM-binding pockets: an attractive target for broad-spectrum antivirals. Trends in Biochemical Sciences, 2023, 48, 420-427.	7.5	9
135	Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies. Journal of Hematology (Brossard, Quebec), 2022, 11, 197-209.	1.0	3
136	Cyclohexylglycylproline attenuates hydrogen peroxide-induced cellular damage mediated by the MDM2-p53 pathway in human neural stem cells. Journal of Cellular Physiology, 2023, 238, 434-446.	4.1	2
138	Identification of p53-target genes in human papillomavirus-associated head and neck cancer by integrative bioinformatics analysis. Frontiers in Oncology, 0, 13, .	2.8	1
139	An overview of novel therapies in advanced clinical testing for acute myeloid leukemia. Expert Review of Hematology, 2023, 16, 109-119.	2.2	1
140	P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway. Nucleic Acids Research, 2023, 51, 1687-1706.	14.5	5
141	Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer. Cancer Discovery, 2023, 13, 1210-1229.	9.4	18
142	The emerging roles of ferroptosis in organ fibrosis and its potential therapeutic effect. International Immunopharmacology, 2023, 116, 109812.	3.8	8
143	The SWIB/MDM2 motif of UBE4B activates the p53 pathway. Molecular Therapy - Nucleic Acids, 2023, 31, 466-481.	5.1	1
144	Abiotic peptides as carriers of information for the encoding of small-molecule library synthesis. Science, 2023, 379, 939-945.	12.6	14
146	Synthesis and Antineoplastic Activity of a Dimer, Spiroindolinone Pyrrolidinecarboxamide. Molecules, 2023, 28, 3912.	3.8	0
148	Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma. Cell Genomics, 2023, , 100321.	6.5	0
149	Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification. Journal of Thoracic Oncology, 2023, 18, 1165-1183.	1.1	3
150	Bilirubin, an endogenous antioxidant that affects p53 protein and its downstream apoptosis/autophagy-related genes in LS180 and SW480 cell culture models of colorectal cancer. Biochemical and Biophysical Research Communications, 2023, 672, 161-167.	2.1	0
151	Interplay of p53 and XIAP protein dynamics orchestrates cell fate in response to chemotherapy. Journal of Theoretical Biology, 2023, 572, 111562.	1.7	0
152	Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges. Therapeutic Advances in Hematology, 2023, 14, .	2.5	1
153	The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy. Frontiers in Immunology, 0, 14, .	4.8	2

#	ARTICLE	IF	CITATIONS
154	Modulation of the ubiquitin-proteasome system by phytochemicals: Therapeutic implications in malignancies with an emphasis on brain tumors. <i>BioFactors</i> , 2023, 49, 782-819.	5.4	4
155	New targeted treatments for advanced sarcomas. <i>Current Opinion in Oncology</i> , 2023, 35, 309-314.	2.4	0
156	Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9571.	4.1	4
157	Small molecules targeting protein-protein interactions for cancer therapy. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4060-4088.	12.0	7
158	Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	0
159	Targeting MDM2 for the development of a new cancer therapy: progress and challenges. <i>Medicinal Chemistry Research</i> , 2023, 32, 1334-1344.	2.4	1
160	Targeting Biomolecular Condensation and Protein Aggregation against Cancer. <i>Chemical Reviews</i> , 2023, 123, 9094-9138.	47.7	5
161	MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation. <i>Biomedicines</i> , 2023, 11, 1879.	3.2	4
162	The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo. <i>Biomedicines</i> , 2023, 11, 1967.	3.2	2
163	Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized Î±-Helical Peptide in Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 9401-9417.	6.4	12
164	Protein-Protein Interactions in Cancer. , 2023, , 43-100.		0
165	MDM2 Influences ACE2 Stability and SARS-CoV-2 Uptake. <i>Viruses</i> , 2023, 15, 1763.	3.3	1
166	Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution. <i>Blood Reviews</i> , 2023, 62, 101130.	5.7	1
167	RNF126, 168 and CUL1: The Potential Utilization of Multi-Functional E3 Ubiquitin Ligases in Genome Maintenance for Cancer Therapy. <i>Biomedicines</i> , 2023, 11, 2527.	3.2	0
168	Moving toward disease modification in polycythemia vera. <i>Blood</i> , 2023, 142, 1859-1870.	1.4	1
169	E3 ubiquitin ligases in nasopharyngeal carcinoma and implications for therapies. <i>Journal of Molecular Medicine</i> , 0, , .	3.9	0
170	Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 101790.	2.7	0
171	Epigenetic biomarkers. , 2024, , 207-257.		0

#	ARTICLE	IF	CITATIONS
172	A Narrative Review of the Carcinogenic Effect of Night Shift and the Potential Protective Role of Melatonin. <i>Cureus</i> , 2023, , .	0.5	0
173	Implications of ubiquitination and the maintenance of replication fork stability in cancer therapy. <i>Bioscience Reports</i> , 2023, 43, .	2.4	1
174	Potential value of mitochondrial regulatory pathways in the clinical application of clear cell renal cell carcinoma: a machine learning-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
175	In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia. , 2023, , 193-242.		0
176	Delivery versus potency in treating brain tumors: BI-907828, a MDM2-p53 antagonist with limited BBB penetration but significant in vivo efficacy in glioblastoma. <i>Molecular Cancer Therapeutics</i> , 0, , .	4.1	1
177	Jianpi Huayu Decoction suppresses cellular senescence in colorectal cancer via p53-p21-Rb pathway: Network pharmacology and in vivo validation. <i>Journal of Ethnopharmacology</i> , 2024, 319, 117347.	4.1	0
178	Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity. <i>Advanced Science</i> , 2024, 11, .	11.2	1
179	Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression. <i>BMC Chemistry</i> , 2023, 17, .	3.8	1
180	Synthesis and Mechanism of p53- ϵ -MDM2 Inhibitors with Heterocyclic Structures: A Focused Review. <i>ChemistrySelect</i> , 2023, 8, .	1.5	0
181	Emerging innovations and advancements in the treatment of extremity and truncal soft tissue sarcomas. <i>Journal of Surgical Oncology</i> , 2024, 129, 97-111.	1.7	1
182	Enhanced <i>TP53</i> reactivation disrupts <i>MYC</i> transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. <i>Science Advances</i> , 2023, 9, .	10.3	1
183	Pancreatic cancer and stem cell. , 2024, , 363-379.		0
184	E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities. <i>Life Sciences</i> , 2024, 336, 122333.	4.3	0
185	Identifying actionable druggable targets for breast cancer: Mendelian randomization and population-based analyses. <i>EBioMedicine</i> , 2023, 98, 104859.	6.1	0
186	One-pot synthesis, structural study, in silico and in vitro anticancer evaluation of spiropyrrolidine oxindoles obtained by the 3-CR of isatin, benzyl amine and a thiazolo[3,2-a]indole derivative. <i>Journal of Molecular Structure</i> , 2024, 1298, 137026.	3.6	0
187	Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis. <i>Carcinogenesis</i> , 0, , .	2.8	0
188	The Mechanism of Ubiquitination or Deubiquitination Modifications in Regulating Solid Tumor Radiosensitivity. <i>Biomedicines</i> , 2023, 11, 3240.	3.2	2
189	Novel therapies upon failure of HMA plus venetoclax. <i>Hematology American Society of Hematology Education Program</i> , 2023, 2023, 702-708.	2.5	0

#	ARTICLE	IF	CITATIONS
190	Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy. <i>Journal of Medicinal Chemistry</i> , 0, , .	6.4	0
191	The Role of p53 in Nanoparticle-Based Therapy for Cancer. <i>Cells</i> , 2023, 12, 2803.	4.1	1
193	ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis. <i>Cancers</i> , 2024, 16, 154.	3.7	1
195	Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. <i>Molecular Biology Reports</i> , 2024, 51, .	2.3	1
196	Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy. <i>Journal of Biomedical Science</i> , 2024, 31, .	7.0	0
197	Development and Nanoparticle-Mediated Delivery of Novel MDM2/MDM4 Heterodimer Peptide Inhibitors to Enhance 5-Fluorouracil Nucleolar Stress in Colorectal Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2024, 67, 1812-1824.	6.4	0
198	Translating p53-based therapies for cancer into the clinic. <i>Nature Reviews Cancer</i> , 2024, 24, 192-215.	28.4	1
199	MDMX in Cancer: A Partner of p53 and a p53-Independent Effector. <i>Biologics: Targets and Therapy</i> , 0, Volume 18, 61-78.	3.2	0
200	Sensitive Methods to Detect Single-Stranded Nucleic Acids of Food Pathogens Based on Cell-Free Protein Synthesis and Retroreflection Signal Detection. <i>Journal of Agricultural and Food Chemistry</i> , 2024, 72, 3783-3792.	5.2	0
201	Ligandability assessment of the C-terminal Rel homology domain of NFAT1. <i>Archiv Der Pharmazie</i> , 0, , .	4.1	0
202	New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics. <i>Biomedicines</i> , 2024, 12, 547.	3.2	0
204	Venetoclax Resistance in Acute Myeloid Leukemia. <i>Cancers</i> , 2024, 16, 1091.	3.7	0
205	p53 biology and reactivation for improved therapy in MDS and AML. <i>Biomarker Research</i> , 2024, 12, .	6.8	0
207	An anti-GD2 aptamer-based bifunctional spherical nucleic acid nanoplatfom for synergistic therapy targeting MDM2 for retinoblastoma. <i>Biomedicine and Pharmacotherapy</i> , 2024, 174, 116437.	5.6	0